New blood tests aim to make haemophilia treatment safer for patients with inhibitors
NCT ID NCT02453542
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study is testing new blood tests to see if they can better measure how well bleeding treatments work in people with haemophilia who have developed inhibitors (antibodies that block standard treatment). The researchers will take blood samples from 20 patients before and after they receive bypassing agents (special clotting medicines). The goal is to improve monitoring, making treatment safer and more effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bypassing agents (FEIBA or NovoSeven)
What this could lead to
If successful, this could lead to better ways to monitor treatment for haemophilia patients with inhibitors, making therapy safer and more effective.
What could go wrong
This is a small, early-stage study with only 20 participants, so results may not apply to all patients. The new tests may not prove reliable enough for routine use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Karolinska University Hospital
RECRUITINGSolna, Stockholm County, 17176, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••